Glidelogic Corporation (PK) News - GDLG | ADVFN

Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

Home
Investing
Stocks
USA
USOTC
Glidelogic Corporation (PK) (GDLG)
Glidelogic Corporation (PK) (GDLG) News

Glidelogic Corporation (PK) (GDLG)

0.25

0.00

( 0.00% )

Updated: 09:30:01

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

FeaturedELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Hosts R&D Event Highlighting the Promise of INF904

Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for...

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company...

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology...

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

InflaRx Appoints Jan Medina as Head of Investor Relations

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

1
Next

Big Brother

Big Brother 1 year ago

Change of control yesterday. Looks like the 2 guys connected to a kind of interesting looking company called Streamline USA Inc, that's been trying to raise $$$'s the last couple years, supposedly in order to compete with Netflix, Hulu, etc in the streaming industry.

https://www.stmln.com/

https://www.sec.gov/cgi-bin/browse-edgar?company=Streamline+USA%2C+Inc&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany

https://www.otcmarkets.com/filing/html?id=16680771&guid=Seu-kHdY-AfFJth

Glidelogic (PK)

NLBNPIT1Y2B7 20240920 11

Delayed Upgrade Clock